Castle Biosciences, Inc. will present innovative research on cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 ASCO Annual Meeting in Chicago, showcasing findings from a collaboration with ...
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results